The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis

Glucocorticoid use may trigger secondary diabetes or exacerbate hyperglycemia in patients with diabetes mellitus (DM). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of patients with type 2 diabetes. Few reports mention liraglutide as a treatment for steroid...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiudan, Chen, Ye, Wang, Jian, Xia, Hong, Zheng, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nagoya University 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236694/
https://www.ncbi.nlm.nih.gov/pubmed/34239182
http://dx.doi.org/10.18999/nagjms.83.2.343
Descripción
Sumario:Glucocorticoid use may trigger secondary diabetes or exacerbate hyperglycemia in patients with diabetes mellitus (DM). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of patients with type 2 diabetes. Few reports mention liraglutide as a treatment for steroid-induced DM (SIDM). Here, we report a patient with SIDM and multiple sclerosis, for whom switching to liraglutide combined with metformin therapy improved glucose levels and ameliorated the symptoms of insulin allergy. Liraglutide may be useful for treating SIDM with insulin allergy.

Ejemplares similares